Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination

NCT00251082 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

391

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopause

Interventions

DRUG: continuous combined estradiol and dydrogesterone
DRUG: continuous combined estradiol and dydrogesterone
DRUG: Placebo

Sponsor

Solvay Pharmaceuticals